Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 586-594

  Quiles, Sherly ^a   Raisch, Kevin P ^b   Sanford, Leisa L ^a   Bonner, James A ^b   Safavy, Ahmad ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; MACROGOL; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOGENICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; IMMUNOCONJUGATES; PACLITAXEL; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77249172711     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm900899g     Document Type: Article

References (41)

1. Kohler, G. M., C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
2. Goodwin, D. A. Stategies for antibody targeting. Antib. Immunoconjugate Radiopharm. 1991, 4, 427-434.
3. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65, 11631-11638.
4. Richman, C. M.; Denardo, S. J.; O'Donnell, R. T.; Yuan, A.; Shen, S.; Goldstein, D. S.; Tuscano, J. M.; Wun, T.; Chew, H. K.; Lara, P. N.; Kukis, D. L.; Natarajan, A.; Meares, C. F.; Lamborn, K. R.; DeNardo, G. L. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 2005, 11, 5920-5927.
5. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279, 377-380.
6. Ma, W. W.; Adjei, A. A. Novel agents on the horizon for cancer therapy. CA: Cancer J. Clin. 2009, 59, 111-137.
7. Safavy, A.; Raisch, K. P.; Khazaeli, M. B.; Buchsbaum, D. J.; Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem. 1999, 42, 4919-4924.
8. Tolcher, A. W.; Sugarman, S.; Gelmon, K. A.; Cohen, R.; Saleh, M.; Isaacs, C.; Young, L.; Healey, D.; Onetto, N.; Slichenmyer, W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17, 478-484.
9. Ojima, I. Guided molecular missiles for tumor-targeting chemotherapy; case studies using the second-generation taxoids as warheads. Acc. Chem. Res. 2008, 41, 108-119.
10. Singh, Y.; Palombo, M.; Sinko, P. J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15, 1802-1826.
11. Akamatsu, Y.; Murphy, J. C.; Nolan, K. F.; Thomas, P.; Kreitman, R. J.; Leung, S. O.; Junghans, R. P. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin. Cancer Res. 1998, 4, 2825-2832.
12. Kreitman, R. J.; Wang, Q. C.; FitzGerald, D. J.; Pastan, I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4-(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer 1999, 81, 148-155.
13. Safavy, A.; Smith, D. C., Jr.; Bazooband, A.; Buchsbaum, D. J. De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. Bioconjugate Chem. 2002, 13, 317-326.
14. Sharkey, R. M.; Goldenberg, D. M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: Cancer J. Clin. 2006, 56, 226-243.
15. Geney, R.; Chen, J.; Ojima, I. Recent advances in the new generation taxane anticancer agents. Med. Chem. 2005, 1, 125-139.
16. Huang, Q.; Kirikae, F.; Kirikae, T.; Pepe, A.; Amin, A.; Respicio, L.; Slayden, R. A.; Tonge, P. J.; Ojima, I. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J. Med. Chem. 2006, 49, 463-466.
17. Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Forman, A. D.; Newton,L.K.;Raber,M.N.;Buzdar,A.U.;Frye,D.K.;Hortobagyi, G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 1991, 83, 1797-1805.
18. Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Ilegbodu, D.; Loesch,D.; Raju, R.; Valentine, E.; Sayre, R.; Cobleigh, M.; Albain, K.; McCullough, C.; Fuchs, L.; Slamon, D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24, 2786-2792.
19. Reichman, B. S.; Seidman, A. D.; Crown, J. P.; Heelan, R.; Hakes, T. B.; Lebwohl, D. E.; Gilewski, T. A.; Surbone, A.; Currie, V.; Hudis, C. A. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 1993, 11, 1943-1951.
20. Seidman, A. D.; Reichman, B. S.; Crown, J. P.; Yao, T. J.; Currie, V.; Hakes, T. B.; Hudis, C. A.; Gilewski, T. A.; Baselga, J.; Forsythe, P. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol. 1995, 13, 1152-1159.
21. Chang, A. Y.; Boros, L.; Asbury, R.; Hui, L.; Rubins, J. Doseescalation study of weekly 1 h paclitaxel administration in patients with refractory cancer. Semin. Oncol. 1997, 24, S17-69-S17-71.
22. Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 1994, 28, S11-S14.
23. Sharma, A.; Mayhew, E.; Bolcsak, L.; Cavanaugh, C.; Harmon, P.; Janoff, A.; Bernacki, R. J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71, 103-107.
24. Payne, J. Y.; Holmes, F.; Cohen, P. R.; Gagel, R.; Buzdar, A.; Dhingra, K. Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. South. Med. J. 1996, 89, 542-545.
25. Rowinsky, E. K.; Donehower, R. C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332, 1004-1014.
26. Safavy, A.; Raisch, K. P.; Matusiak, D.; Bhatnagar, S.; Helson, L. Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule. Bioconjugate Chem. 2006, 17, 565-570.
27. Safavy, A.; Bonner, J. A.; Waksal, H.; Buchsbaum, D. J.; Gillespie, G. Y.; Khazaeli, M. B.; Arani, R. B.; Chen, D. T.; Carpenter, M.; Raisch, K. P. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chem. 2003, 14, 302-310.
28. Safavy, A.; Georg, G. I.; Vander Velde, D.; Raisch, K. P.; Safavy, K.; Carpenter, M.; Wang, W.; Bonner, J. A.; Khazaeli, M. B.; Buchsbaum, D. J. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward optimization of the linker structure. Bioconjugate Chem. 2004, 15, 1264-1274.
29. Naramura, M.; Gillies, S. D.; Mendelsohn, J.; Reisfeld, R. A.; Mueller, B. M. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 1993, 37, 343-349.
30. Goldstein, N. I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311-1318.
31. Karashima, T.; Sweeney, P.; Slaton, J. W.; Kim, S. J.; Kedar, D.; Izawa, J. I.; Fan, Z.; Pettaway, C.; Hicklin, D. J.; Shuin, T.; Dinney, C. P. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin. Cancer Res. 2002, 8, 1253-1264.
32. Reusch, U.; Sundaram, M.; Davol, P. A.; Olson, S. D.; Davis, J. B.; Demel, K.; Nissim, J.; Rathore, R.; Liu, P. Y.; Lum, L. G. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin. Cancer Res. 2006, 12, 183-190.
33. Thompson, D. M.; Gill, G. N. The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv. 1985, 4, 767-788.
34. Schlessinger, J. The epidermal growth factor receptor as a multi-functional allosteric protein. Biochemistry 1988, 27, 3119-3123.
35. Carpenter, G.; Cohen, S. Epidermal growth factor. Annu. Rev. Biochem. 1979, 48, 193-216.
36. Pathak, M. A.; Matrisian, L. M.; Magun, B. E.; Salmon, S. E. Effect of epidermal growth factor on clonogenic growth of primary human tumor cells. Int. J. Cancer 1982, 30, 745-750.
37. Singletary, S. E.; Baker, F. L.; Spitzer, G.; Tucker, S. L.; Tomasovic, B.; Brock, W. A.; Ajani, J. A.; Kelly, A. M. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987, 47, 403-406.
38. Real, P. J.; Benito, A.; Cuevas, J.; Berciano, M. T.; de Juan, A.; Coffer, P.; Gomez-Roman, J.; Lafarga, M.; Lopez-Vega, J. M.; Fernandez-Luna, J. L. Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res. 2005, 65, 8151-8157.
39. Reilly, R. M.; Chen, P.; Wang, J.; Scollard, D.; Cameron, R.; Vallis, K. A. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J. Nucl. Med. 2006, 47, 1023-1031.
40. Deutsch, H.; Glinski, J.; Hernandez,M.; Haugwitz, R.; Narayanan, V.; Suffness, M.; Zalkow, L. Synthesis of congeners and prodrugs: water soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 1989, 32, 788-792.
41. Luo, Y.; Prestwich, G. D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem. 1999, 10, 755-763.